Shares of Nuvectra Corp. (NASDAQ:NVTR) have been assigned an average broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Analysts have set a 1-year consensus price target of $11.00 for the company and are anticipating that the company will post ($0.88) EPS for the current quarter, according to Zacks. Zacks has also assigned Nuvectra Corp. an industry rank of 112 out of 265 based on the ratings given to related companies.
NVTR has been the subject of a number of recent research reports. B. Riley initiated coverage on shares of Nuvectra Corp. in a research note on Wednesday, September 21st. They issued a “buy” rating and a $12.00 price objective for the company. Piper Jaffray Cos. restated a “neutral” rating and issued a $10.00 price objective (down previously from $12.00) on shares of Nuvectra Corp. in a research note on Saturday, August 13th.
Shares of Nuvectra Corp. (NASDAQ:NVTR) opened at 6.29 on Friday. The company’s market capitalization is $64.64 million. Nuvectra Corp. has a 52-week low of $4.02 and a 52-week high of $11.64. The firm’s 50 day moving average is $6.72 and its 200-day moving average is $7.30.
Nuvectra Corp. (NASDAQ:NVTR) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28. The business earned $2.50 million during the quarter, compared to analyst estimates of $2.40 million. The business’s revenue for the quarter was up 66.7% on a year-over-year basis. Equities research analysts anticipate that Nuvectra Corp. will post ($3.37) earnings per share for the current fiscal year.
Nuvectra Corp. Company Profile
Nuvectra Corporation, formerly QIG Group, LLC, is a neurostimulation company. The Company is focused on the development and commercialization of a neurostimulation technology platform, which is used for the treatment of various disorders through stimulation of tissues associated with the nervous system.